Literature DB >> 22693300

Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement.

Dimitrios Christidis1, Shaifali Jain, Bhaskar Das Gupta.   

Abstract

A 63-year-old female presented with a 12-week history of worsening proximal pain and stiffness. She was diagnosed with polymyalgia rheumatica and started on corticosteroids. The authors were unable to wean-off her steroid treatment, despite trying various steroid sparing agents on different occasions with no benefit. In August 2010, she was diagnosed with giant cell arteritis with a temporal artery biopsy and ultrasound of the temporal and axillary arteries. An fluorine-18-deoxyglucose positron emission tomography CT showed increased uptake in the aorta and major vessels, in keeping with widespread large vessel involvement. Due to the disease severity, the failure of previous disease-modifying agents and the development of steroid related sideeffects, the authors decided to treat her with intravenous tocilizumab (TCZ;an interleukin 6 blocker). After her first infusion, the patient reported excellent response with normalisation of her inflammatory markers. Prednisolone reduced from 20 mg to 3.5 mg /day after five infusions of TCZ (8 mg/kg).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22693300      PMCID: PMC3132621          DOI: 10.1136/bcr.04.2011.4135

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Authors:  R N Maini; P C Taylor; J Szechinski; K Pavelka; J Bröll; G Balint; P Emery; F Raemen; J Petersen; J Smolen; D Thomson; T Kishimoto
Journal:  Arthritis Rheum       Date:  2006-09

2.  Color duplex ultrasonography in the diagnosis of temporal arteritis.

Authors:  W A Schmidt; H E Kraft; K Vorpahl; L Völker; E J Gromnica-Ihle
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

3.  The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal.

Authors:  V M Corrigall; A L Dolan; B Dasgupta; G S Panayi
Journal:  Br J Rheumatol       Date:  1997-09

4.  Giant-cell arteritis producing an aortic arch syndrome.

Authors:  G G Hunder; L E Ward; M K Burbank
Journal:  Ann Intern Med       Date:  1967-03       Impact factor: 25.391

5.  Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  B Dasgupta; G S Panayi
Journal:  Br J Rheumatol       Date:  1990-12

6.  Disease pattern in cranial and large-vessel giant cell arteritis.

Authors:  A Brack; V Martinez-Taboada; A Stanson; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1999-02

7.  Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Authors:  Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

8.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.

Authors:  N E Roche; J W Fulbright; A D Wagner; G G Hunder; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1993-09

9.  Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.

Authors:  M De Silva; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

10.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Authors:  Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2007-08
View more
  16 in total

1.  Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.

Authors:  M Yates; Y K Loke; R A Watts; A J MacGregor
Journal:  Clin Rheumatol       Date:  2013-09-12       Impact factor: 2.980

Review 2.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

Review 3.  Biologic Therapy for the Treatment of Giant Cell Arteritis.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Rodney Tehrani; Walter Jay
Journal:  Neuroophthalmology       Date:  2014-04-02

Review 4.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

Review 5.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

Review 6.  Tocilizumab: a new therapy for large vessel vasculitis.

Authors:  Ibrahim A Al-Homood
Journal:  Clin Exp Med       Date:  2013-08-15       Impact factor: 3.984

7.  Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

Authors:  Éric Toussirot; Alexis Régent; Valérie Devauchelle-Pensec; Alain Saraux; Xavier Puéchal
Journal:  RMD Open       Date:  2016-08-31

8.  Clinical use of biologics in vasculitis syndromes.

Authors:  Marino Paroli
Journal:  Biologics       Date:  2012-10-25

Review 9.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580

Review 10.  Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy.

Authors:  Shunsuke Mori; Yukinori Koga
Journal:  Clin Rheumatol       Date:  2014-05-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.